This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Mon, 02/12/2024 - 15:22 February 12, 2024 — Sensome , a company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild Smart Guidewire in peripheralarterydisease (PAD).
New Guidelines on PeripheralArteryDisease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies 4. Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5.
a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheralarterialdisease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.
However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheralarterydisease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology.
The Efemoral Vascular Scaffold System (EVSS) offers a new approach to treating peripheralarterial occlusive disease (PAOD) by addressing the specific anatomic challenges and complex biomechanics of patients with athero-occlusive disease in the leg. The global burden of peripheralarterydisease.
The care team there successfully treated a 78-year-old male with peripheral vascular disease using the Philips device. Developing and driving clinical evidence is crucial to improving care and guiding the adoption of new technologies like the Philips laser atherectomy and lithotripsy system,” said Drs.
CLTI is the most severe form of peripheralarterialdisease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary arterydisease. 1 To date, interventional treatment of coronary arterydisease with drug-eluting stents has been able to establish flow angiographically. of the U.S.
13, 2024Sensome hasannounced positive results from two studies of its Clotild Smart Guidewire System demonstrating its ability to successfully identify fresh clot thrombus rich in red blood cells (RBCs) in peripheralarterydisease (PAD) and differentiate it from other tissue encountered during PAD procedures.
Elixir Medical Corporation, a privately-held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheralarterydisease. Shown here: Elixir Medical CEO Motasim Sirhan. The LithiX IVL System is not approved for sale in the U.S. Calcified coronary lesions.
The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary arterydisease. The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions, according to a written statement on the designation.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary arterydisease (CAD) and peripheralarterydisease (PAD).
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary arterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.
We were fortunate to be the first in the Southwest to use such technology.” the Neuroguard IEP 3-in-1 carotid stent and post-dilation balloon system is designed to deliver a self-expanding carotid artery stent while using a special filter to prevent emboli (blockage) debris from reaching the brain. Designed by Raleigh, N.C.-based
a medical device company dedicated totreating peripheralarterialdisease (PAD), recently announceit received WCG Institutional Review Board (IRB) approval for the ELITE-BTK Pivotal Trial of its MAGNITUDEDrug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee PeripheralArterialDisease (PAD).
Common Vascular Conditions We Treat Some vascular diseases affect your arteries while others occur in your veins. Atherosclerosis & ArterialDiseasesPeripheralArteryDisease (PAD) : A blockage in your legs. Carotid ArteryDisease : A blockage or narrowing in the arteries supplying your brain.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content